ADIAL PHARMACEUTICALS, INC. (ADIL)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 6, 2026

Verified against EDGAR
Total Assets
$29.1M
Stockholders' Equity
-$38.4M
Cash & Equivalents
$28.7M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, ADIAL PHARMACEUTICALS, INC. reported net income of -$52.0M and total assets of $29.1M. Every figure below is taken directly from ADIAL PHARMACEUTICALS, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$8.0M
FY2024—-$13.2M
FY2023—-$5.1M
FY2022—-$12.7M
FY2021—-$19.4M
FY2020—-$10.9M
FY2019—-$8.6M
FY2018—-$11.6M
FY2017—-$1.1M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 28, 2026on EDGAR ↗
10-Q/AOct 21, 2026on EDGAR ↗
8-KOct 16, 2026on EDGAR ↗
8-KOct 2, 2026on EDGAR ↗
8-KSep 18, 2026on EDGAR ↗
8-KSep 16, 2026on EDGAR ↗
8-KAug 25, 2026on EDGAR ↗
DEF 14AAug 24, 2026on EDGAR ↗
8-KAug 21, 2026on EDGAR ↗
8-KAug 17, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$29.1Msource ↗
Stockholders’ Equity-$38.4Msource ↗
Cash & Equivalents$28.7Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$52.0Msource ↗
Operating Income-$52.0Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$440,000source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-11.25source ↗
EPS (basic)$-11.25source ↗
Shares Outstanding2.6Msource ↗
Cash from Operations-$6.4Msource ↗
Cash from Financing$25.2Msource ↗
Cash from Investing—source ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
5
Sells
0
Net shares
+40.0K

Restatement history

Point-in-time

3 of 174 annual fact-keys were materially restated between filings: what ADIAL PHARMACEUTICALS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches ADIL’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/ADIL

MCP tool: get_sec_fundamentals ticker=ADIL

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/ADIL/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=ADIL as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/ADIL/history

MCP tool: get_fundamentals_history ticker=ADIL

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/ADIL

MCP tool: get_financial_health ticker=ADIL

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.